Salvina Therapeutics is developing novel antibodies targeting TNF to overcome efficacy barriers in inflammatory and autoimmune diseases.
Salvina Therapeutics has raised $545K in total funding. The most recent round was Grant. The last funding was announced in October 2023.
Salvina Therapeutics's investors include BaseLaunch.
Salvina Therapeutics is headquartered in Allschwil, Switzerland.
Salvina Therapeutics is developing novel antibodies targeting TNF to overcome efficacy barriers in inflammatory and autoimmune diseases.
Salvina Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Salvina Therapeutics — Funding & Investors." VCBacked, October 2, 2023, https://www.vcbacked.co/company/salvina-therapeutics. Accessed September 30, 2026.
VCBacked. (2023). Salvina Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/salvina-therapeutics
{{cite web |title=Salvina Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/salvina-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated